Phone: 888-558-5227

651-644-8424 Email: getinfo@lktlabs.com

888-558-7329 Fax:

Web: lktlabs.com

Product Information

Product ID P0246

CAS No. 914913-88-5

Chemical Name

Synonym P529

Formula C₂₄H₂₂O₆ Formula Wt. 406.43

Melting Point

Purity ≥98%

Solubility DMSO 81 mg/mL (199.29


mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

Description Palomid 529 inhibits mTORC1/2 and exhibits anticancer chemotherapeutic and anti-angiogenic activities. Palomid 529 is

currently in clinical trials as a potential treatment for macular degeneration. In mice with BRCA-1-deficient breast cancer tumors, palomid 529 inhibits tumor growth. Palomid 529 also inhibits angiogenesis and vascular permeability in cellular models. Additionally, palomid 529 indirectly inhibits downstream Akt signaling.



Bulk quanitites available upon request

Product ID	Size
P0246	1 mg
P0246	5 mg
P0246	10 mg

References Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. PMID: 23689994.

> Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 2011 May 26;30 (21):2443-50. PMID: 21242970.

Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.